Loading
A phase 3 trial of Gamunex-C, 10% Injectable Solution in non-Hodgkin lymphoma, run by Grifols Biologicals, LLC, now recruiting.
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma is a phase 3 interventional study registered as NCT07582432 by Grifols Biologicals, LLC, with 49 participants planned, started 2026-04-23 and due to reach its primary completion in 2028-08-31. Interventions recorded: Gamunex-C, 10% Injectable Solution.
Shares Grifols, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.